Would you re-test ecnoglutide after four weeks at 30 °C, or accept the original certificate?

Concretely: ecnoglutide · four weeks · 30 °C.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

What would you do, and what would make you change course?

The relevant detail is that the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Reconciling gross mass to label claim

Specifically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

If testing multiple vials, state how many you tested and why you chose those vials.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

The relevant detail is that if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Put another way, for a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 13 Oct 2024 by fresh_bac — expanded the table to cover the lower concentration

Two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If testing multiple vials, state how many you tested and why you chose those vials.

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 28 Jul 2024 by Dr_Yusuf_Adeyemi — added a caveat about sampling